Name | 5-Fluoro-2-{(Z)-[4-oxo-2-(tetrahydro-1(2H)-pyridazinyl)-1,3-thiazol-5(4H)-ylidene]methyl}phenyl 1-pyrrolidinecarboxylate |
---|---|
Synonyms |
MFCD28166314
1-Pyrrolidinecarboxylic acid, 5-fluoro-2-[(Z)-[4-oxo-2-(tetrahydro-1(2H)-pyridazinyl)-5(4H)-thiazolylidene]methyl]phenyl ester 5-Fluoro-2-{(Z)-[4-oxo-2-(tetrahydro-1(2H)-pyridazinyl)-1,3-thiazol-5(4H)-ylidene]methyl}phenyl 1-pyrrolidinecarboxylate |
Description | CLP290 is an orally available activator of the neuron-specific K+-Cl− cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ rats[1][2]. |
---|---|
Related Catalog | |
Target |
KCC2[1] |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 553.7±60.0 °C at 760 mmHg |
Molecular Formula | C19H21FN4O3S |
Molecular Weight | 404.458 |
Flash Point | 288.6±32.9 °C |
Exact Mass | 404.131836 |
LogP | 2.89 |
Vapour Pressure | 0.0±1.5 mmHg at 25°C |
Index of Refraction | 1.691 |